Introduction
On September 14, 2011, the International Diabetes Federation announced that 336 million people worldwide now have type 2 diabetes, and that the disease is responsible for 4.6 million deaths each year, or one death every seven seconds. It affects 12% of US adults and >25% of those over the age of 65. Diabetes is no longer restricted to the Western world, and the greatest increases in disease incidence in the next few decades are expected to be in China and India. These figures serve to emphasize that there is currently a fast-growing diabetes pandemic. This is a major healthcare problem because diabetes increases the risk of heart disease, stroke, and microvascular complications such as blindness, renal failure, and peripheral neuropathy. Consequently, it places a severe economic burden on governments and individuals: the cost of diabetes and its complications amounts to $612 million per day in the US alone.
Diabetes is characterized by high blood glucose levels as a result of insufficient insulin for the body's needs. It is a heterogeneous disorder with multiple etiologies. Type 1 diabetes (T1DM) is an autoimmune disease that results in b cell destruction. It usually presents in childhood, accounts for 5%-10% of all diabetes, and is associated with the presence of islet-cell antibodies, and patients require lifelong insulin; it will not be considered further here. Type 2 diabetes (T2DM), the most common form of the disease, is influenced by lifestyle factors, such as age, pregnancy, and obesity, but has a strong genetic component. Multiple genes are thought to be involved, each producing a small effect on T2DM risk. An increasing number of rare monogenic forms of diabetes that result from mutations in a single gene have also been identified. They amount to 1%-2% of all diabetes in Europe, and almost all are characterized by reduced insulin secretion. Accumulating evidence also implicates impaired insulin release in T2DM.
The last decade has seen an explosion of new information about the mechanism of insulin secretion and the genetic causes of diabetes, emphasizing the importance of impaired b cell function in both polygenic and monogenic disease. This Review focuses on these recent findings.
Insulin Secretion from the Pancreatic b Cell
The physiological regulation of insulin secretion from the pancreatic b cells is now fairly well understood. Exocytosis of insulin granules requires an increase in intracellular calcium that (at least in the case of glucose-induced insulin secretion) results almost entirely from calcium influx through plasmalemmal voltage-gated calcium channels ( Figure 1A ). Their opening is controlled by the ATP-sensitive potassium (K ATP ) channel, which plays a pivotal role in insulin secretion by linking cell metabolism to the membrane potential. At low plasma glucose levels, this channel is open and K + efflux through the open pore keeps the membrane hyperpolarized, preventing electrical activity, calcium channel opening, calcium influx, and insulin secretion. An increase in plasma glucose leads to increased glucose uptake and metabolism by the b cell and thus to a rise in metabolically generated ATP and a concomitant fall in MgADP. These changes in adenine nucleotide concentrations close K ATP channels, thereby initiating electrical activity, calcium influx, and insulin secretion. Sulphonylurea drugs, such as glibenclamide, also stimulate insulin secretion by closing K ATP channels, but they do so by binding directly to the channel, thus bypassing the metabolic steps. These drugs have been used for almost 60 years to treat T2DM and, more recently, certain monogenic forms of diabetes.
Glucose metabolism also has effects downstream of K ATPchannel closure and calcium influx that result in amplification of insulin secretion. The details of the mechanism are still not fully understood, but the end result is an increase in the release probability of the secretory granules. Glucose is almost unique among nutrients in that it has the capacity to initiate insulin secretion. Other fuels such as amino acids and fatty acids enhance glucose-induced insulin secretion but generally have little stimulatory effect on their own. As a consequence, insulin secretion is dependent on glucose metabolism.
Hormones and neurotransmitters also modulate insulin secretion, primarily by influencing the release competence of the insulin granules without elevating intracellular calcium. Current interest is focused on glucagon-like peptide-1 (GLP-1), which is released from gut L cells in response to the presence of glucose and other nutrients in the gut lumen and potentiates insulin secretion. It stimulates b cell production of intracellular cAMP, which acts by PKA-dependent and PKA-independent mechanisms to amplify granule exocytosis, as well as by enhancing K ATP -channel closure, b cell electrical activity, and calcium release from intracellular stores (reviewed in Leech et al., 2011) . Most of these effects manifest only at elevated plasma glucose levels, thus accounting for the glucose dependence of GLP-1-potentiated insulin secretion. Release of incretin hormones in the gut, such as GLP-1 and GIP, explains why an oral glucose challenge produces a much larger stimulation of insulin secretion than an intravenous glucose challenge.
The PKA-independent effects of incretins are mediated by the cAMP-sensing protein Epac2 (also known as cAMP-GEFII). Recently, Epac2 was also shown to be a target of sulphonylureas ; it remains to be determined whether this effect contributes (together with its effect on the K ATP channel) to the stimulation of insulin secretion by these drugs, but there is some evidence that sulphonylureas enhance exocytosis in b cells (Eliasson et al., 2003) . Just as activation of PKA or PKC (e.g., in response to acetylcholine) enhances Ca 2+ -dependent exocytosis without further elevation of intracellular calcium, other agents (such as adrenaline and somatostatin) inhibit glucosestimulated insulin secretion even when intracellular calcium is elevated, possibly by activating the protein phosphatase calcineurin (Rorsman and Renströ m, 2003) . Insulin secretion from isolated islets is biphasic, an initial rapid transient peak being followed by a slowly developing second phase of release. In T2DM, first-phase insulin secretion is almost abolished, and second-phase secretion is strongly reduced (Hosker et al., 1989) . It has been proposed that the biphasic nature of insulin secretion reflects the existence of distinct functional pools within the b cells. A subset of secretory granules known as the readily releasable pool (by analogy with nerve terminals), situated close to the Ca 2+ channels, accounts for first-phase secretion. Once this pool has been depleted, exocytosis proceeds at a much lower rate, possibly reflecting the physical translocation of new granules (''newcomer granules'') to the release sites, producing second-phase release. Like neurotransmitter secretion, insulin granule exocytosis requires the SNARE proteins synaptobrevin, syntaxin, and SNAP25 (Rorsman and Renströ m, 2003) . The existence of functionally distinct subsets of secretory granules is supported by FRET-based studies (Takahashi et al., 2010) , which demonstrated that b cell SNARE complexes exist in different states of ''preassembly.'' Granules with preassembled SNARE complexes underwent rapid exocytosis upon stimulation. In addition, a time-and Ca
2+
-dependent assembly of SNARE complexes that preceded a slower phase of exocytosis was observed. It is tempting to equate these two sets of granules with first-and second-phase release and to speculate that glucose metabolism may enhance the release competence of the secretory granules by promoting assembly of the SNARE complex. This might explain the elusive amplifying effect of glucose on insulin secretion.
Monogenic Diabetes
An increasing number of clinically and genetically distinct forms of diabetes that result from mutations in single genes have been described (Table 1) . Conventionally, monogenic diabetes that develops within the first 6 months of life has been referred to as neonatal diabetes (ND), and that which develops in young adults as maturity-onset diabetes of the young (MODY). The latter term is misleading, however, as monogenic diabetes is quite distinct from maturity-onset diabetes (an old name for T2DM). The different genes involved also give rise to clinically distinct types of diabetes that vary in the age of onset, severity of hyperglycemia, and risk of complications. In this section, therefore, we refer to the different forms of monogenic diabetes by their gene names and to MODY as young-onset diabetes (Murphy et al., 2008) .
Considerable advances in our understanding of the genetic causes of monogenic diabetes have been made in the last 10 years, largely because of the careful clinical and genetic identification of these subgroups of patients. These have provided valuable insights into b cell function, as well as the diagnosis and pathophysiology of the disease. In some instances, this knowledge has also led to a change in therapy for affected patients. Consequently, individuals with neonatal or youngonset diabetes that is not accompanied by islet autoantibodies should be evaluated genetically. This is important, as monogenic diabetes is often misdiagnosed as T1DM (or even T2DM).
For convenience, we consider neonatal diabetes and youngonset diabetes separately, although it is now clear that mutations in the same gene may manifest their effects at different ages. Neonatal Diabetes ND, usually defined as diabetes diagnosed within the first 6 months of life, was once considered a rare variant of T1DM that presented unusually early. Within the last decade, however, it has become clear that ND is a monogenic disorder that is caused by mutations in genes that play key roles in b cell function or development, including glucokinase, the K ATP channel, and insulin itself. The incidence of ND is low (around 1 in 200,000 live births). It may be permanent (PNDM) or transient (TNDM) or follow a remitting-relapsing time course. Rarely, a few individuals may present with diabetes between 6 and 9 months of age (Rubio-Cabezas et al., 2011) . The disease is usually associated with intrauterine growth retardation and a lower birth weight, in keeping with the role of insulin as a growth factor. In marked contrast to T1DM, islet-cell antibodies are absent.
Gain-of-function mutations in the genes encoding the Kir6.2 (KCNJ11) and SUR1 (ABCC8) subunits of the K ATP channel are the most common cause of PNDM, accounting for around 50% of cases (Flanagan et al., 2009; Hattersley and Ashcroft, 2005) . All ND mutations impair the ability of metabolism to close the channel by enhancing either ATP block at Kir6.2 or channel activation by Mg nucleotides (MgADP/MgATP) at SUR1 . This leads to an increased K ATP current, which prevents b cell depolarization in response to glucose metabolism and consequently impairs insulin secretion. Most mutations in KCNJ11 occur spontaneously, and patients are heterozygotes. ABCC8 mutations are genetically more heterogeneous with dominant, recessive, uniparental disomy and compound heterozygous inheritance being described .
In addition to diabetes, around 20% of patients with K ATPchannel mutations have a constellation of neurological symptoms (Hattersley and Ashcroft, 2005) . A minority (3%) have ''DEND syndrome,'' which is characterized by severe mental and motor developmental delay, epilepsy, and neonatal diabetes, as well as muscle hypotonia, hyperactivity, and balance problems. However, most have an intermediate disorder (iDEND syndrome) that resembles DEND syndrome but without the epilepsy.
The spectrum of symptoms found in iDEND and DEND reflects the widespread tissue distribution of K ATP channels, which link cell metabolism to plasmalemmal electrical activity in muscle, heart, and brain as well as pancreatic b cells. Mouse models indicate that the motor problems originate in the central nervous system rather than muscle, which may be related to the different SUR isoforms in these tissues (SUR1 in neurons, SUR2A in muscle) . There is a good correlation between genotype and phenotype, with those mutations that have the greatest functional effect on ATP sensitivity producing a more severe clinical phenotype .
ND patients were originally treated with insulin as they were assumed to have an unusually early form of T1DM, but the discovery in 2004 of the causal role of K ATP channels has enabled 90% of patients (>500 to date) to switch to sulphonylurea therapy. These drugs block their open K ATP channels, thereby stimulating insulin secretion. This results in a significant improvement in diabetes control: fluctuations in glucose homeostasis are reduced and HbA1C levels fall, which should translate into a reduced risk of diabetic complications (Pearson et al., 2006; Zung et al., 2004) . In some patients the accompanying neurological problems also show some improvement (Mlynarski et al., 2007; Slingerland et al., 2006 ).
There is a good correlation between the efficacy of sulphonylureas at blocking K ATP -channel activity and the ability of patients with the same mutation to transfer to oral drug therapy. Those with the most severe mutations, which cause DEND syndrome, are often unable to transfer because their mutant channels are not blocked sufficiently by glibenclamide . The efficacy of sulphonylurea therapy also shows some interesting differences between patients with ND and those (Servitja and Ferrer, 2004) with T2DM. In 50% of patients with T2DM, sulphonylureas cease to be effective at controlling blood glucose levels within a few years of beginning therapy. This phenomenon is known as secondary failure, and its mechanism is unknown. Because drug therapy has been implemented so recently, it is not clear whether patients with KCNJ11 or ABCC8 mutations will continue to respond to sulphonylureas in the long term. Nevertheless, this seems likely as a few patients have been successfully treated with these drugs for many years, and to date, no desensitization to glibenclamide has been observed (Iafusco et al., 2011) . The ability of some adult ND patients to transfer to sulphonylurea therapy implies that their b cells are fully functional, despite many years of suboptimal glucose control. They often need much higher drug doses, relative to body weight, than T2DM patients (Pearson et al., 2006) , probably because their K ATP channels are more active at ambient glucose levels and thus require (at least initially) a higher drug dose to close them to the same extent as a lower dose would in ''normal'' b cells. Some mutant channels are also less sensitive to sulphonylureas.
Recent studies indicate that heterozygous mutations in the insulin gene (INS) account for around 20% of cases of PNDM. Most coding mutations are de novo mutations and are inherited in a dominant manner (Støy et al., 2007) . One of these is identical to that found in the Akita mouse, where it acts to disrupt insulin biosynthesis, causing the protein to be degraded so that few insulin granules are produced, despite one Ins2 and two Ins1 alleles remaining functional (Wang et al., 1999) . By analogy, the human mutations are predicted to prevent normal protein folding and induce the unfolded protein response, leading to endoplasmic reticulum (ER) stress and b cell death. Recessively acting mutations, which reduce insulin synthesis, have also been reported (Garin et al., 2010) . Insulin therapy is essential for patients with INS mutations.
Homozygous loss-of-function mutations in the glucokinase gene (GCK) can cause PNDM but are extremely rare (Njølstad et al., 2001) . Glucokinase catalyzes the first step in glucose oxidation-phosphorylation of the sugar-and has been termed the glucose sensor of pancreatic b cells (Matschinsky, 2009) . The complete absence of insulin secretion in patients lacking glucokinase reveals that ATP production from glucose is essential for insulin secretion and cannot be substituted by ATP produced by protein or fat metabolism. The importance of glucokinase for insulin secretion is illustrated by the finding that the sulphonylurea glibenclamide reversibly increased both basal and glucagon-stimulated insulin secretion in a patient with a homozygous GCK mutation, leading to a reduced insulin dose and lower HBA1c level (Turkkahraman et al., 2008) . However, insulin therapy could not be stopped, perhaps because ATP generation was not sufficient to support the amplifying effect of glucose on insulin secretion.
TNDM accounts for 50% of cases of ND. Diabetes presents within the first few weeks after birth but remits within several months or years, only to often return in adolescence or early adult life. The most common cause (70%) is an abnormality in the imprinted region of chromosome 6q24 that leads to overexpression of at least two imprinted genes, ZAC and HYMAI Temple and Shield, 2010) . It remains unclear how this results in diabetes, or why the diabetes is transient, although a mouse model that overexpressed these two genes recapitulated the clinical phenotype (Ma et al., 2004) . Most other cases of TNDM are due to activating mutations in KCNJ11 and ABCC8 and can be treated with sulphonylureas. Considerable overlap exists with PNDM, with the same mutation sometimes causing PNDM in some family members and TNDM in others. Why the disease follows a remitting-relapsing time course is also an enigma.
Recessive mutations in a number of other genes cause a range of very rare syndromes that include ND as one component of a multisystem disorder (Table 1) . Young-Onset Diabetes Familial young-onset diabetes is typically diagnosed outside the neonatal period but before 25 years of age. Mutations in the glucokinase and HNF1A genes account for about 70% of cases. Heterozygous loss-of-function mutations in the glucokinase gene (GCK) lead to lifelong, mild, stable fasting hyperglycemia from birth. However, this is often only detected later in life, such as during routine screening in pregnancy (Osbak et al., 2009) . GCK mutations act by decreasing glucose-dependent ATP production, which results in impaired K ATP closure and reduced insulin secretion. Treatment is rarely needed and 85% of patients can be managed by diet alone. Microvascular complications are also rare, reflecting the fact that glucose homeostasis is not severely impaired.
Five genes associated with familial young-onset diabetes are transcription factors that interact in a complex network to regulate gene transcription (Table 1) . They are needed both for correct functioning of adult b cells and for b cell development. The most common mutations are found in the homeobox genes HNF1A and HNF4A; mutations in HNF1B, IPF1, and NEUROD1 are more rare. Most mutations cause a loss of function and are inherited in an autosomal-dominant manner. They lead to a progressive deterioration of b cell function, increasing hyperglycemia, and eventual diabetes. Studies of mouse models suggest that the impaired insulin secretion may be a result of defective metabolism (Dukes et al., 1998) . Whereas heterozygous mutations cause a phenotype that is largely confined to the b cell, homozygous mutations in these transcription factors cause a range of additional effects, reflecting the role of these proteins in extrapancreatic tissues. For example, HNF1A is associated with a low renal glucose threshold, HNF4A with altered lipids and lipoproteins, and HNF1B with renal cysts and uterine and genital developmental disorders. Patients are at risk of microvascular complications due to poor glucose control.
Patients with HNF1A mutations are highly sensitive to sulphonylureas and can transfer from insulin to low-dose oral drug therapy without deterioration of glycemic control (Pearson et al., 2003) . This indicates that despite diabetes of long duration, they possess sufficient b cell mass, and thus that HNF1A likely controls b cell function.
It is evident from the above discussion that the age at which monogenic diabetes presents is variable and depends on the functional severity of the mutation. Patients with more severe mutations, or a greater gene dosage (homozygous rather than heterozygous), tend to develop diabetes earlier in life, whatever the gene involved. In many cases, they may also exhibit extrapancreatic symptoms. Furthermore, common variants in the same genes that cause monogenic disease may predispose to T2DM in later life.
Polygenic Diabetes
Genetics of T2DM Perhaps one of the most radical changes in the field in the past decade has been widespread recognition that reduced b cell function is the key problem in T2DM. Ten years ago, many leading groups still continued to regard T2DM as largely a disease of insulin resistance; today, this is not the case. In part, this paradigm shift has come about because studies of human islets have shown reduced glucose-dependent insulin secretion in T2DM even when allowance is made for the reduction of insulin content (Figure 2 ). In part, it derives from linkage studies and genome-wide association studies (GWAS), which have identified more than 40 genes associated with increased risk of T2DM over the past 5-6 years. Here we discuss a selection of these genes; for a more comprehensive summary, see Bonnefond et al. (2010) and McCarthy (2010) .
Most gene associations were inferred from single-nucleotide polymorphisms (SNPs) within noncoding regions of the gene, and in many cases the annotation is not yet conclusive. Thus it remains uncertain whether diabetes is linked to the gene within whose intron the SNP resides or to genes that lie close by or are coregulated. With few exceptions, the genes identified were unexpected based on existing knowledge, and precisely how they predispose to T2DM is not yet understood. However, many are believed to be important for b cell function, b cell development, or the regulation of b cell mass (Bonnefond et al., 2010; McCarthy, 2010) . Others, such as FTO, predispose toward obesity and thus indirectly to T2DM; when corrected for body mass index, the association with T2DM vanishes.
The most important diabetes susceptibility gene identified to date is TCF7L2, which increases diabetes risk 1.7-fold. It is involved in WNT signaling, and functional studies suggest that it influences insulin secretion, although there is disagreement about whether its expression is increased (Lyssenko et al., 2007) or unaltered (Kirkpatrick et al., 2010) in T2DM. However, downregulation of TCF7L2 in mouse or human islets causes reduced insulin secretion and exocytosis (Shu et al., 2008) .
Several GWAS genes are implicated in cell-cycle regulation and thus suggested to act by influencing b cell mass during development. This is not entirely unexpected because a reduced b cell mass might predispose to T2DM by reducing the capacity to cope with an increased demand, such as that imposed by age and/or obesity.
The functional effects of other genes are less clear. The zinc transporter Znt8 (SLC30A8) is necessary for the uptake of zinc into the insulin granules and formation of Zn-complexed insulin crystals (Sladek et al., 2007) . Thus one might expect it to have an effect on insulin storage or release; however, deleting the gene in mice has only weak and variable effects (Lemaire et al., 2009) . KCNQ1 (Yasuda et al., 2008 ) encodes a voltagesensitive K channel, and a gain-of-function mutation in this gene might be expected to reduce action potential duration and thereby calcium influx and insulin secretion. However, it is uncertain whether KCNQ1 is present in human b cells, and whether the intronic SNP influences its expression. A common polymorphism in Kir6.2 (E23K) predisposes to T2DM (Gloyn et al., 2003) . Although the increase in disease risk is small (odds ratio, 1.2), the population risk is highly significant because 65% of people carry at least one K allele. The E23K polymorphism is found in strong linkage disequilibrium with another variant, S1369A, in the adjacent SUR1 gene, which means either variant could cause the increased disease risk. Precisely how the polymorphism increases disease risk remains controversial, as functional effects on K ATP -channel activity are very small and variable.
What these examples serve to show is that it is not easy to determine how the various SNPs predispose to T2DM. Given that genes found in GWAS only cause a small increase in disease risk and that their effects manifest only later in life or in the face of obesity, disease-associated SNPs may only have small effects on b cell function that will be hard to measure in human studies or even in vitro. As might be expected, disease risk is enhanced for individuals who carry multiple risk-associated SNPs (McCarthy, 2010) . Even taking this into consideration, GWAS genes collectively appear to explain only 5%-10% of T2DM. This has led to the suggestion that there may be a large number of far less common mutations, private to each individual, that carry a greatly enhanced disease risk (Bonnefond et al., 2010) . Much current effort is devoted to identifying these rare variants.
Over the last 5 years, a vast amount of information about the genetics of T2DM has been obtained. What is lacking is an understanding of the functional roles of many of these genes and how they contribute to T2DM. Addressing this problem will require considerable effort, substantial funding, and a multidisciplinary approach-incorporating studies of human islets, generation and analysis of mouse models (lacking or overexpressing the gene of interest), molecular and cellular studies, and, perhaps most importantly, in vivo studies in humans carrying these different variants. But before beginning this task, it will be essential to determine precisely which gene(s) is affected by any intronic T2DM susceptibility SNP of interest. What Can Rodent Models Teach Us? Not all T2DM genes identified in the last decade were found by GWAS or linkage studies. Some were found by analysis of genes that cause glucose intolerance or diabetes in rodents. For example, the discovery that the a 2 -adrenoreceptor gene contributes to diabetes in the GK rat led to identification of a common variant of this gene that decreases insulin secretion in humans (Rosengren et al., 2010) . In fact, deletion of a number of different genes in mice impairs glucose tolerance. This indicates that glucose homeostasis is finely balanced and involves many pathways, and that perturbation of any of these can cause glucose intolerance.
As much work on the mechanism of insulin secretion has involved rodents, particularly genetically modified mice, it is pertinent to consider the extent to which rodents provide a valid model of human insulin secretion. In some instances, mouse models faithfully recapitulate the human phenotype, as in the case of ND due to KCNJ11 mutations Girard et al., 2009) . Nevertheless, it is now evident that human and mouse b cells are far from identical; e.g., they express different complements of ion channels and membrane transporters (Braun et al., 2008; De Vos et al., 1995) and have a different architecture. Thus although mouse models and studies of mouse islets are very valuable, it is important to be cautious when extrapolating from mice to humans.
Is T2DM Associated with Reduced b Cell Mass?
There is an ongoing debate about the extent to which b cell mass is reduced in T2DM, and its precise role in the etiology of T2DM remains controversial. Over the last decade, several investigators have come to favor the hypothesis that a reduced number of b cells rather than impaired b cell function is a major factor in the development of T2DM. A decrease in b cell mass of up to 60% has been reported in T2DM (Butler et al., 2003) , which parallels the extent of reduction in glucose-induced insulin secretion (Del Guerra et al., 2005) . However, others have found considerably lower decrements (Rahier et al., 2008) . Because no longitudinal studies of b cell mass in man exist, it is unclear whether individuals with T2DM started with a lower b cell mass or if this developed as a consequence of sustained hyperglycemia.
How much b cell mass is needed to maintain glycemia is also uncertain. Simple calculations based on the rate of insulin release each day in a nondiabetic individual suggest that as few as 40% of b cells would be sufficient for adequate glucose control. This number is supported by the fact that removal of half the pancreas has only a small effect on glucose tolerance (Menge et al., 2008) . Collectively, these findings suggest that although b cell mass plays some role in T2DM, it is not the only, or even the most important, factor. The finding that insulin secretion from T2DM islets is reduced even when allowance is made for a slight reduction of insulin content (Figure 2) implicates b cell function rather than b cell number in the etiology of T2DM. Indeed, the rapid reversal of diabetes and the increase in insulin secretion provoked by GLP-1 demonstrate that even in established T2DM, there is sufficient, albeit latent, b cell capacity.
Recent observations suggest that unlike islet cells in young rodents, adult human b cells are largely senescent, postmitotic, and long lived (Cnop et al., 2010; Kö hler et al., 2011) , so aberrant cellular turnover is unlikely to contribute to T2DM. However, aging processes (e.g., reduced mitochondrial oxidation) in long-lived endocrine cells could impair secretory function. Amyloid formation in pancreatic islets, from islet amyloid polypeptide (IAPP), is a hallmark of T2DM, but because the severity of amyloidosis is low in most patients, it is likely to be a consequence rather than a cause of the disease (Clark and Nilsson, 2004) .
Environmental and Lifestyle Factors
Although this Review focuses on the role of the b cell in diabetes, it is important to briefly consider its role in relation to insulin resistance. The impact of obesity on T2DM risk is truly dramatic, and the catastrophic increase in T2DM over the past 50 years is largely due to the concomitant increase in obesity-diabetes would be reduced to a manageable problem if only obesity could be controlled.
Obesity is a key risk factor for T2DM as it lowers insulin sensitivity in peripheral tissues. The b cells compensate for this by upregulating insulin secretion (Bergman, 2005) , and the degree to which they are able to do so determines whether or not the individual develops diabetes. This, in turn, is influenced by their genetic constitution. This explains why most obese people, and those with other insulin-resistant states, do not develop T2DM: their b cells are able to compensate. A dramatic illustration of the interplay between diabetes, obesity, and genetics is provided by the report that infusion of triglyceride emulsion led to a decrease in insulin secretion in people who had first-degree relatives with T2DM but not in those who did not (Kashyap et al., 2003) . All individuals were nondiabetic in the absence of elevated plasma triglyceride, emphasizing that it is only in the presence of elevated fat that genetic differences become obvious.
Lipids have complex effects on b cell function. In the short term, free fatty acids (FFAs) potentiate glucose-induced insulin secretion. This contributes to the increased insulin secretion following a mixed meal and enables storage of excess calories as fat. It has also been proposed to account for the compensatory upregulation of b cell function in response to insulin resistance (Stefanovski et al., 2011) . In the long term, however, FFAs suppress glucose-induced insulin secretion. The mechanism by which this occurs is still hotly debated. It has been suggested to involve impaired glucose metabolism, reduced insulin biosynthesis, and b cell loss (Poitout and Robertson, 2008; Yaney and Corkey, 2003) . A further idea has recently been proposed, based on the lack of any change in Ca 2+ currents or global [Ca 2+ ] i transients in the presence of physiological levels of FFA during fasting and the observation that Ca 2+ channels become more diffusely distributed in the plasmalemma (Hoppa et al., 2009 ). The b cell has a low density of calcium channels that normally colocalize with the secretory granules, ensuring that even if calcium channels open only briefly (as during a brief action potential), Ca 2+ entry is sufficient to trigger exocytosis ( Figure 1B) . Loss of this colocalization means that although the calcium channels continue to open, the resulting increase in [Ca 2+ ] i occurs in the ''wrong'' place and fails to evoke secretion (Hoppa et al., 2009 ). Obesity and high-fat feeding mimic the effects of long-term incubation of islets with FFAs on insulin secretion and Ca 2+ -channel distribution (Collins et al., 2010) . All correlate with an increased amount of fat within the islets (Hoppa et al., 2009 ) and the surrounding exocrine pancreas (Pinnick et al., 2008) . Moreover, in Zucker diabetic rats fed a high-fat diet, an increase in islet triglyceride content precedes hyperglycemia (Lee et al., 1994) . There is also an inverse correlation between the amount of fat in the human pancreas and glucose-induced insulin secretion, with glucose tolerance and insulin secretion improving in parallel with a reduction in pancreatic fat (Tushuizen et al., 2007) . This raises the interesting possibility that intrapancreatic/intraislet fat depositions provide a long-term local source of FFA that adversely affects b cell function.
How Do Studies of Monogenic Diabetes Inform Our Understanding of T2DM?
Recent years have seen considerable advances in our understanding of the genetic origin and associated phenotype of several types of monogenic diabetes. The confounding effects of obesity are less important in these disorders, suggesting that it may be possible to glean information on the etiology of T2DM by comparing it with monogenic diabetes.
Current evidence favors the idea that insufficient glucosestimulated insulin secretion is primarily responsible for T2DM. As discussed above, estimates of b cell mass in T2DM vary but do not appear sufficient to account for the disease. Moreover, the ability of GLP-1, or bariatric surgery, to restore glucose-induced insulin secretion and plasma glucose to normal levels in patients with T2DM argues that neither b cell mass nor insulin content is severely reduced. This implicates defective b cell function as the cause of T2DM.
Where does this defect occur? As T2DM is not associated with impaired secretion from other endocrine organs, metabolic and exocytotic pathways common to all endocrine cells cannot be adversely affected; it must be some process unique to the b cell. Given the key role of K ATP channels and the ability of sulphonylureas to enhance insulin secretion in T2DM, it is tempting to attribute the impaired insulin secretion to slight overactivity of K ATP channels. However, any such overactivity cannot be as great as in ND patients with K ATP -channel mutations because agents such as arginine and GLP-1, which work only when K ATP channels are largely closed, are still effective secretagogs in T2DM but not in ND. These considerations suggest that T2DM may be associated with mild impairment of metabolism and/or the K ATP channel itself, leading to a small reduction in K ATP -channel closure when blood glucose increases. A key question is whether this is sufficient to explain the diabetes.
Reduced activity of glucokinase cannot be solely responsible for T2DM as the phenotype of the disease does not mimic that of patients with either heterozygous or homozygous GCK mutations. Impaired mitochondrial metabolism has been postulated to contribute to T2DM (Maechler and Wollheim, 2001) , and an age-dependent decline in mitochondrial function might help explain why T2DM develops later in life (in lean individuals). However, if impaired metabolic regulation of K ATP -channel activity were the only problem in T2DM, then the phenotype would resemble that of patients with ND or GCK mutations, which it does not. This suggests that additional processes, downstream of K ATPchannel closure, that regulate the amplifying response to glucose or exocytosis itself also contribute to T2DM. Together with a slight deterioration of metabolic function and insulin content with age, these might lead to impaired glucose tolerance, thus setting in progress a vicious cycle in which slight hyperglycemia produces downregulation of critical genes, impairs the amplifying effects of glucose, and leads to a progressive decline in b cell function (Weir and Bonner-Weir, 2004) . Obesity, via insulin resistance, would place an increased functional demand on the b cell and accelerate b cell failure.
Therapies for T2DM
As T2DM progresses, blood glucose levels rise and b cell function progressively declines. Treatment options are complex, with patients starting on oral antidiabetic agents, but most soon proceeding to insulin injections; many also take drugs that reduce insulin resistance. Almost all of the current therapeutic interventions lead to weight gain and an increased risk of hypoglycemia and have little if any impact on disease progression.
Recent years have seen the introduction of incretin-based therapies. GLP-1 has a half-life of 1 min in the plasma and is rapidly degraded by the enzyme dipeptidyl peptidase 4 (DPP4), so it cannot be used itself (Deacon et al., 2008) . However, inhibitors of DPP4, or stable GLP-1 analogs, are very effective at enhancing glucose-stimulated insulin secretion. Their efficacy demonstrates that even in people with diabetes of long duration, sufficient b cell capacity exists to maintain normoglycemia, supporting the idea that impaired b cell function is the prime cause of the disease. In rodents, GLP-1 also increases islet cell functional mass (Xu et al., 1999) , although it is uncertain whether this applies to human islets (Parnaud et al., 2008) . Plasma GLP-1 levels are lower in T2DM, but the extent to which a diminished incretin effect contributes to disease progression is unknown (Holst, 2007) . Most recently, agonists against novel G protein-coupled receptors, including GPR119, GPR40, GPR120, and GPR43 (Kebede et al., 2009) , that have the potential to stimulate not only pancreatic b cells but also the cells in the gut that release incretin hormones have emerged as possible treatments for diabetes. In addition, anti-inflammatory agents, such as interleukin-1-receptor antagonists, that improve glycemic control and b cell function are entering trial programs (Mandrup-Poulsen et al., 2010) .
Diabetes is usually considered to be a chronic disease, associated with a progressive reduction in b cell mass and irreversible b cell failure that cannot be cured and requires lifelong therapy. However, over the past 10 years, two independent sets of studies have challenged this view. First, severe energy restriction was able to reverse established T2DM within 1 week (Lim et al., 2011) . Second, patients who undergo bariatric surgery often show remission of diabetes long before there is any substantial weight loss (Karra et al., 2010) .
The purpose of bariatric surgery is to enhance weight loss in morbid obesity. Two different types of gastric bypass are routinely employed: gastric banding and Roux-en-Y bypass (RYGB) (Karra et al., 2010) . Intriguingly, both methods result in a rapid resolution (within days) of T2DM (Karra et al., 2010) . Meta-analysis indicated that diabetes resolves in 70% of patients after RYGB and somewhat fewer patients after gastric banding (Buchwald et al., 2009 ). The rapid improvement of glucose tolerance cannot be accounted for by the weight loss, which is much slower, but is associated with increased insulin sensitivity and often (but not always) increased insulin secretion (Falké n et al., 2011; Isbell et al., 2010) . The mechanisms involved have not yet been elucidated, but proposed explanations include increased release of the incretin hormone GLP-1, an altered gut microbiotic environment, and caloric restriction. Bariatric surgery is so effective that in 2011 it was approved by the International Diabetes Federation as an appropriate therapy for morbidly obese patients with T2DM.
Interestingly, the effects of bariatric surgery can be mimicked by a very low-calorie diet (600 kcal/day) (Lim et al., 2011) , which normalizes plasma glucose levels within 4-7 days. In itself, this is not so remarkable. During World War II, the number of people with newly diagnosed T2DM in several European countries crashed, only to rise after the end of food rationing (despite the restricted diet, people were not starving) (Figure 3) (Westlund, 1966) . In the most recent Balkan war, glycemic control significantly improved in T2DM patients, as did obesity (Kulenovic et al., 1996) . However, there have been few studies of how reduced caloric intake leads to diabetes remission. The significance of the study by Lim and colleagues (Lim et al., 2011) is that it illustrates just how fast diabetes resolves. This correlates with a marked fall in hepatic glucose output and insulin resistance, which normalizes glycemia. The underlying mechanism is unclear. There is also a gradual restoration of glucose-induced biphasic insulin secretion that mirrors a reduction in pancreatic fat content. This suggests that a factor derived from intrapancreatic fat depots may exert a negative effect on b cell function. The identity of this factor remains unknown, but local release of FFAs is one of several possible candidates.
Conclusions
The last 10 years have seen major advances in both the scientific understanding and the treatment of diabetes. PNDM has been recognized as a monogenic disorder, separate from T1DM, with which it was previously confused. The understanding of the molecular basis of ND and the introduction of a novel therapy (oral sulphonylureas) for patients with K ATP channel or HNF1A mutations constitute a real breakthrough. Importantly, tailoring therapy to an individual's genetic constitution in this way has led to improved glycemic control and a far better quality of life.
There has also been unprecedented progress in identification of genes that are highly significantly associated with T2DM. Like any discovery, their identification precipitates a plethora of new questions and heralds a daunting amount of new functional work. But it also provides an opportunity for gaining important new insights into b cell function. Although it was always appreciated that T2DM is a polygenic disease, few would probably have guessed how many genes are involved, or which ones they would turn out to be. Indeed, the 40 genes identified already are enough that each diabetic could have their own unique combination of gene variants underlying their disease. At present, known SNPs are of little or no value in predicting an individual's risk of T2DM, clinical translation has so far been minimal, and it remains to be seen whether they will be of therapeutic value. Rather, their importance lies in the insights they provide into the pathophysiology of disease and potential therapeutic targets. Unraveling their roles will be challenging but rewarding.
The idea that multiple genes and multiple etiologies underlie T2DM suggests that there will be an associated multiplicity of phenotypes. One lesson from monogenic diabetes studies is that different genotypes are associated with distinct phenotypes, a finding of considerable significance for disease diagnosis, choice of therapy, and an understanding of disease mechanism. This suggests that it will be important to phenotype T2DM patients more fully. A valuable approach might be to focus on lean T2DM patients, where the confounding effects of obesity and insulin resistance are minimal.
Finally, we point out that although there is a strong genetic predisposition to T2DM, shared by many of the population, most people are not doomed to become diabetic. The massive increase in diabetes incidence in recent years is not due to genetic changes but is a consequence of the rise in obesity. It is clear that weight control is highly beneficial in T2DM, and recent studies show that it is even possible to reverse established disease by bariatric surgery and caloric restriction (at least in patients who have had diabetes for only a few years). The big problem is that dietary compliance is very difficult to achieve and is rarely perfect. Thus it may be appropriate to consider radical measures such as taxing high-fat foods, as has recently been implemented in Denmark. The examples of cigarette smoking and alcohol intake suggest that such a tax might be an effective deterrent to excess consumption.
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